Latest news
21 August 2020
Touchlight announces development of a vaccine against COVID-19
Hampton, London, UK – 21 August 2020 Touchlight is pleased to announce it has begun development of a vaccine against SARS-CoV-2 (COVID-19). Bringing together Touchlight’s technology with a team of vaccine development and infectious and respiratory disease experts, this program seeks to augment the existing vaccine development landscape, guided by emerging clinical data and the … Continued
29 July 2020
Cancer Research UK, University of Southampton and Touchlight Genetics Partner to develop head and neck cancer vaccine
Hampton, London, Southampton, UK – 29 July 2020 Cancer Research UK, the University of Southampton and Touchlight Genetics, a London based biotechnology company, today (Wednesday) announce a new clinical development partnership to progress a therapeutic DNA vaccine, TGL-100, into an early phase clinical trial targeting head and neck squamous cell carcinoma (HNSCC). HNSCC is the … Continued
18 June 2020
Touchlight to develop biobatteries with potential to address limitations of portable power supply
Hampton, UK – 18 June 2020 – Supported by the Office of Naval Research Global (ONR Global) and the Defense Science and Technology Laboratory (DSTL), Touchlight, a biotechnology company focused on the discovery and development of DNA-based genetic medicines, is working together with the Minteer Lab, University of Utah, to develop a DNA-enabled biobattery that could … Continued
5 June 2020
Touchlights’s chairman to help lead UK COVID-19 vaccine effort
Dr. Clive Dix appointed as Deputy Head of the UK’s Vaccine Taskforce Hampton, UK – 5 June 2020 – Touchlight, a biotechnology company focused on the discovery and development of DNA-based genetic medicines, today commented on the news that its Chairman, Dr. Clive Dix, has been appointed Deputy Chair of the UK’s Vaccine Taskforce. In this … Continued
27 April 2020
Touchlight appoints Dr. Helen Horton as Chief Research Officer
Former J&J Senior Scientific Director and immunology expert joins at a pivotal time Touchlight driving its dbDNA technology towards clinical development in therapeutic and prophylactic vaccines Hampton, UK – 27 April 2020 – Touchlight, a biotechnology company focused on the discovery and development of DNA-based genetic medicines, today announces the appointment of Dr. Helen Horton as … Continued
Upcoming events
mRNA-based therapeutics summit
Join us at the mRNA-based therapeutics summit in Boston, US (July 26-28, 2023).
Our team will be available to discuss your advanced therapy manufacturing. Learn how our enzymatically produced DNA vector called doggybone DNA (dbDNA) can significantly improve speed to manufacture, safety and scalability in comparison to plasmid DNA, for vaccine development.